Last updated: October 2026 AMT-130 (ifezuntirgene inilparvovec) is a one-time gene therapy being developed by uniQure for Huntington’s disease. It is delivered through a neurosurgical procedure and is designed to reduce production of the mutant huntingtin protein. Current status Public company and regulatory updates indicate that AMT-130 remains one of the most advanced HD treatment…